Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection

From OmniJournal
Revision as of 05:25, 22 July 2020 by Jtodaro2 (talk | contribs) (Created page with "Category:Article Category:Covid19 {| class="infobox" width=200px |class="publication"|'''Publication''' |- |Title || <ul>[https://onlinelibrary.wiley.com/doi/10.1002/j...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Publication
Title
Authors
  • A Ferreira, MD PhD
  • A Oliveira-e-Silva, MD
  • P Bettencourt, MD PhD
Journal Journal of Medical Virology
Date July 9, 2020

Retrospective analysis of patients with systemic lupus erythematosus, rheumatoid arthritis and other autoimmune disorders showed that patients receiving hydroxychloroquine had an odds ratio of COVID-19 of 0.51 (CI 0.37-0.70) compared to patients with autoimmune diseases who were receiving other therapeutics.

This analysis suggests a prophylactic effect of hydroxychloroquine against COVID-19.

Of note, hydroxychloroquine was not shown to be entirely protective against COVID-19 as 5.96% of patients receiving chronic treatment with hydroxychloroquine still became infected with novel-coronavirus compared to the 7.45% infection incidence in patients not receiving hydroxychloroquine.

Major Issues

No major issues identified.

Minor Issues

No minor issues identified.

Impact

This is another retrospective analysis that suggests a prophylactic effect of hydroxychloroquine against COVID-19.

Article Revisions

None at this time.

References